Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,878
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.90 | 44.00 | -0.49% |
| CAC 40 | 8,124.88 | 56.26 | 0.70% |
| DAX 40 | 24,229.91 | 43.42 | 0.18% |
| Dow JONES (US) | 48,416.56 | 41.49 | -0.09% |
| FTSE 100 | 9,751.31 | 102.28 | 1.06% |
| HKSE | 25,185.63 | 443.25 | -1.73% |
| NASDAQ | 23,057.41 | 137.76 | -0.59% |
| Nikkei 225 | 49,523.56 | 644.55 | -1.28% |
| NZX 50 Index | 13,430.89 | 22.75 | 0.17% |
| S&P 500 | 6,816.51 | 10.90 | -0.16% |
| S&P/ASX 200 | 8,605.20 | 42.10 | -0.49% |
| SSE Composite Index | 3,819.89 | 48.04 | -1.24% |